Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2024)
16 slides from Immuron's shareholder meeting presentation, Nov 18, 2024
Slide 1: Immuron 2024 AGM Presentation ASX Announcement
Immuron 2024 AGM Presentation Highlights: • Global sales increased 172% in FY24 to $4.90m; Record Travelan® sales of $4.86m • Record monthly sales in October 2024 of $1.49m • Completed and reported topline results for Travelan® Phase 2 and NMRC’s Campylobacter clinical trial; planning 2H2025 Phase 3
Slide 2: Immuron Platform Technology and IMM-124E (Travelan)
10 days of returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term travel
Slide 3: References and Forward-Looking Statements
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Immuron AGM Presentation, November 2024
For personal use only AGM PRESENTATION 18 NOVEMBER, 2024 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only • Platform Technology: capable of producing highly specific or
Slide 7: Naval Medical Research Command Trial
NAVAL MEDICAL RESEARCH COMMAND TRIAL NMRC experimental campylobacter/ETEC vaccine o The trial was funded by the Naval Medical Research Command (NMRC). Immuron’s produced a hyperimmune bovine colostrum (HBC) For personal use only trial product using the NMRC vaccine which was tested in a controlled h
Slide 8: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs For personal use only Compound or Indication Phase Phase Phase Market brand name I II III Traveler’s IMM-124E Diarrhea ETEC Travelan® challenge Clostridioides difficile IMM-529 Infection & Recurrence Our Partners’ Clinical Program
Slide 9: Travelan Progresses Towards Phase 3
TRAVELAN® PROGRESSES TOWARDS PHASE 3 Travelan® (IMM-124E) Phase 2 o Travelan® IND Approval – December 2022 o Study Initiation – May 2023 For personal use only o First cohort recruitment completed – July 2023 o Presentations at Military Health System Research Symposium – August 2023 o Second cohort r
Slide 10: IMM-529 Progression to Phase 2
IMM-529 PROGRESSION TO PHASE 2 IMM-529 Clinical Development for Treatment of C. difficile Infections o Opportunity Assessment completed by For personal use only o C. difficile infection (CDI) affects just over ~400,000 people in the US annually o Sizable number of patients who experience at least on
Slide 11: Immuron's Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 For personal use only bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the
Slide 12: Continued Strong Sales Growth
CONTINUED STRONG SALES GROWTH For personal use only o Global sales increased by 172% in the 2024 fiscal year to a o USA record A$4.90 million compared to A$1.80 million in FY23 o FY24: a record A$1.08 million; up 67% o Record monthly sales in October 2024 of $1.49 million o Q1, FY25: A$0.28 million
Slide 13: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only 10
Slide 14: Consumer Marketing Activity Driving Travelan Sales Growth
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, For personal use only consideration and engagement o Ranging across major retailers (Australia, Canada) o In-store positioning and promotion o Retailer catalogues o Search and social media marketing o Social c
Slide 15: Steven Lydeamore, Chief Executive Officer – Contact Information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 12
Slide 16: Scientific References
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of